FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134384677> ?p ?o ?g. }

• W3134384677 endingPage "401" @default.
• W3134384677 startingPage "401" @default.
• W3134384677 abstract "401 Background: Considerable numbers of patients (pts) with metastatic urothelial carcinoma (mUC) (approximately 25-47%) develop bone metastases (BoM). Their impact on the efficacy of immunotherapy (IO) is not yet sufficiently investigated. We developed a national collaboration on this issue, with the aim to assess the effect of BoM on survival outcomes of immunotherapy-treated pts in a large retrospective cohort. Methods: Data on pts diagnosed with mUC and treated between 07/14 and 08/20 with single-agent immunotherapy (IO) after failure of at least 1 previous line of chemotherapy (CT) for advanced disease, or (neo-)adjuvant CT within 12 months were retrospectively collected across 14 centers. PFS and OS were analyzed using the Kaplan-Meier method. Cox regression analysis was performed evaluating potential prognostic factors for OS and PFS. Each factor was evaluated in univariable (UV) and multivariable (MVA) analysis. Results: A total of 208 evaluable pts treated with single-agent immunotherapy (anti PD-1 n=42; anti PD-L1 n=166) were identified, including 122 without BoM (59% BoM-) and 86 (41%) BoM+. 13% of pts had progressed within 12 months after (neo-)adjuvant CT and 79% after a previous line of platinum-based CT for advanced disease (cisplatin 42.8%; carboplatin 36.5%). The presence of BoM negatively affected performance status (PS) of patients at baseline (ECOG PS 0/1/2 in 58% / 37% / 5% in BoM- vs 38% / 52% / 9% in BoM+; p=0.017). Other baseline characteristics were comparable. BoM+ showed shorter PFS (median 2.0 vs 2.6 months, HR 1.76 [95%CI, 1.31-2.37], p<0.001) and OS (median 3.9 vs 7.8 months, HR 1.59 [95%CI, 1.15-2.20], p=0.005) than BoM-. Probability of being alive was 62% vs 40% after 6 months, 38% vs 23% after 1 year and 24% vs 13% after 2 years, in BoM- and BoM+ respectively. Within each Bellmunt score, PFS and OS of BoM+ pts were shorter compared to BoM-. Both BoM and higher Bellmunt risk score were significantly associated with shorter PFS and OS in UV and MV analyses (Table). Conclusions: Patients with mUC treated with single-agent immunotherapy for BoM+ advanced disease have a dismal prognosis compared with BoM-. Further research is needed to understand the mechanism behind these clinical outcomes. [Table: see text]" @default.
• W3134384677 created "2021-03-15" @default.
• W3134384677 creator A5000621664 @default.
• W3134384677 creator A5004473647 @default.
• W3134384677 creator A5007575010 @default.
• W3134384677 creator A5008661123 @default.
• W3134384677 creator A5013913173 @default.
• W3134384677 creator A5019981707 @default.
• W3134384677 creator A5020987606 @default.
• W3134384677 creator A5024134152 @default.
• W3134384677 creator A5030345469 @default.
• W3134384677 creator A5034433849 @default.
• W3134384677 creator A5037756908 @default.
• W3134384677 creator A5040427285 @default.
• W3134384677 creator A5058849092 @default.
• W3134384677 creator A5061243125 @default.
• W3134384677 creator A5071060598 @default.
• W3134384677 creator A5075400298 @default.
• W3134384677 creator A5083331837 @default.
• W3134384677 creator A5083659627 @default.
• W3134384677 creator A5090061046 @default.
• W3134384677 date "2021-02-20" @default.
• W3134384677 modified "2023-10-16" @default.
• W3134384677 title "A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study)." @default.
• W3134384677 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.401" @default.
• W3134384677 hasPublicationYear "2021" @default.
• W3134384677 type Work @default.
• W3134384677 sameAs 3134384677 @default.
• W3134384677 citedByCount "1" @default.
• W3134384677 countsByYear W31343846772022 @default.
• W3134384677 crossrefType "journal-article" @default.
• W3134384677 hasAuthorship W3134384677A5000621664 @default.
• W3134384677 hasAuthorship W3134384677A5004473647 @default.
• W3134384677 hasAuthorship W3134384677A5007575010 @default.
• W3134384677 hasAuthorship W3134384677A5008661123 @default.
• W3134384677 hasAuthorship W3134384677A5013913173 @default.
• W3134384677 hasAuthorship W3134384677A5019981707 @default.
• W3134384677 hasAuthorship W3134384677A5020987606 @default.
• W3134384677 hasAuthorship W3134384677A5024134152 @default.
• W3134384677 hasAuthorship W3134384677A5030345469 @default.
• W3134384677 hasAuthorship W3134384677A5034433849 @default.
• W3134384677 hasAuthorship W3134384677A5037756908 @default.
• W3134384677 hasAuthorship W3134384677A5040427285 @default.
• W3134384677 hasAuthorship W3134384677A5058849092 @default.
• W3134384677 hasAuthorship W3134384677A5061243125 @default.
• W3134384677 hasAuthorship W3134384677A5071060598 @default.
• W3134384677 hasAuthorship W3134384677A5075400298 @default.
• W3134384677 hasAuthorship W3134384677A5083331837 @default.
• W3134384677 hasAuthorship W3134384677A5083659627 @default.
• W3134384677 hasAuthorship W3134384677A5090061046 @default.
• W3134384677 hasConcept C121608353 @default.
• W3134384677 hasConcept C126322002 @default.
• W3134384677 hasConcept C126894567 @default.
• W3134384677 hasConcept C141071460 @default.
• W3134384677 hasConcept C143998085 @default.
• W3134384677 hasConcept C167135981 @default.
• W3134384677 hasConcept C2776694085 @default.
• W3134384677 hasConcept C2777701055 @default.
• W3134384677 hasConcept C2777863537 @default.
• W3134384677 hasConcept C2778239845 @default.
• W3134384677 hasConcept C2780352672 @default.
• W3134384677 hasConcept C2781451048 @default.
• W3134384677 hasConcept C2911057145 @default.
• W3134384677 hasConcept C3019882237 @default.
• W3134384677 hasConcept C50382708 @default.
• W3134384677 hasConcept C71924100 @default.
• W3134384677 hasConcept C72563966 @default.
• W3134384677 hasConceptScore W3134384677C121608353 @default.
• W3134384677 hasConceptScore W3134384677C126322002 @default.
• W3134384677 hasConceptScore W3134384677C126894567 @default.
• W3134384677 hasConceptScore W3134384677C141071460 @default.
• W3134384677 hasConceptScore W3134384677C143998085 @default.
• W3134384677 hasConceptScore W3134384677C167135981 @default.
• W3134384677 hasConceptScore W3134384677C2776694085 @default.
• W3134384677 hasConceptScore W3134384677C2777701055 @default.
• W3134384677 hasConceptScore W3134384677C2777863537 @default.
• W3134384677 hasConceptScore W3134384677C2778239845 @default.
• W3134384677 hasConceptScore W3134384677C2780352672 @default.
• W3134384677 hasConceptScore W3134384677C2781451048 @default.
• W3134384677 hasConceptScore W3134384677C2911057145 @default.
• W3134384677 hasConceptScore W3134384677C3019882237 @default.
• W3134384677 hasConceptScore W3134384677C50382708 @default.
• W3134384677 hasConceptScore W3134384677C71924100 @default.
• W3134384677 hasConceptScore W3134384677C72563966 @default.
• W3134384677 hasIssue "6_suppl" @default.
• W3134384677 hasLocation W31343846771 @default.
• W3134384677 hasOpenAccess W3134384677 @default.
• W3134384677 hasPrimaryLocation W31343846771 @default.
• W3134384677 hasRelatedWork W1481820868 @default.
• W3134384677 hasRelatedWork W2303091494 @default.
• W3134384677 hasRelatedWork W2382328728 @default.
• W3134384677 hasRelatedWork W2471989939 @default.
• W3134384677 hasRelatedWork W2751375968 @default.
• W3134384677 hasRelatedWork W3046420943 @default.
• W3134384677 hasRelatedWork W3202746846 @default.
• W3134384677 hasRelatedWork W4226023057 @default.
• W3134384677 hasRelatedWork W4226202055 @default.
• W3134384677 hasRelatedWork W4302319510 @default.

• next